Midwest Professional Planners LTD. Invests $308,000 in BioNTech SE (NASDAQ:BNTX)

Midwest Professional Planners LTD. purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,377 shares of the company’s stock, valued at approximately $308,000.

Several other hedge funds have also recently bought and sold shares of BNTX. Baillie Gifford & Co. bought a new position in shares of BioNTech during the 1st quarter worth $735,723,000. Price T Rowe Associates Inc. MD grew its stake in shares of BioNTech by 31.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock worth $226,559,000 after acquiring an additional 500,085 shares during the period. Coatue Management LLC bought a new position in BioNTech in the 1st quarter worth about $37,326,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in BioNTech in the 1st quarter worth about $30,171,000. Finally, Polar Capital Holdings Plc bought a new position in BioNTech in the 1st quarter worth about $24,568,000. Institutional investors own 14.49% of the company’s stock.

BioNTech stock traded up $10.50 during mid-day trading on Wednesday, reaching $345.38. 14,308 shares of the stock traded hands, compared to its average volume of 3,083,459. The stock has a market capitalization of $83.76 billion, a PE ratio of 17.52 and a beta of -1.59. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.67 and a quick ratio of 2.57. BioNTech SE has a 12-month low of $58.81 and a 12-month high of $464.00. The business’s 50-day moving average is $321.74 and its 200-day moving average is $221.83.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Sunday, August 8th. The company reported $10.77 EPS for the quarter, beating analysts’ consensus estimates of $8.35 by $2.42. The company had revenue of $5.31 billion during the quarter, compared to analysts’ expectations of $3.27 billion. BioNTech had a return on equity of 159.73% and a net margin of 52.48%. BioNTech’s revenue for the quarter was up 12599.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) earnings per share. Equities analysts anticipate that BioNTech SE will post 37.71 EPS for the current fiscal year.

Several research analysts have commented on BNTX shares. Wolfe Research started coverage on BioNTech in a research note on Monday, July 19th. They issued an “outperform” rating and a $248.00 target price for the company. Bryan, Garnier & Co upgraded BioNTech from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 11th. SVB Leerink raised their target price on BioNTech from $159.00 to $293.00 and gave the stock a “market perform” rating in a research note on Friday, August 13th. Redburn Partners restated a “sell” rating and issued a $146.00 target price on shares of BioNTech in a research note on Wednesday, June 16th. They noted that the move was a valuation call. Finally, The Goldman Sachs Group downgraded BioNTech from a “buy” rating to a “neutral” rating in a research report on Sunday, August 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $200.62.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

See Also: Trade War

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.